138 related articles for article (PubMed ID: 26503049)
1. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MC; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; ; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Quinn M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJ; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; deFazio A; Grimmond SM; Bowtell DD
Nature; 2015 Nov; 527(7578):398. PubMed ID: 26503049
[No Abstract] [Full Text] [Related]
2. Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.
Cacan E
Cell Biol Int; 2017 Mar; 41(3):328-339. PubMed ID: 28074529
[TBL] [Abstract][Full Text] [Related]
3. CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target.
Feng X; Bai X; Ni J; Wasinger VC; Beretov J; Zhu Y; Graham P; Li Y
Front Oncol; 2019; 9():557. PubMed ID: 31380263
[No Abstract] [Full Text] [Related]
4. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.
Ju W; Yoo BC; Kim IJ; Kim JW; Kim SC; Lee HP
Oncol Res; 2009; 18(2-3):47-56. PubMed ID: 20066894
[TBL] [Abstract][Full Text] [Related]
5. Chemoresistant ovarian cancer enhances its migration abilities by increasing store-operated Ca
Huang HK; Lin YH; Chang HA; Lai YS; Chen YC; Huang SC; Chou CY; Chiu WT
J Biomed Sci; 2020 Feb; 27(1):36. PubMed ID: 32079527
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
7. Heat Shock Protein 60 (HSP60) Serves as a Potential Target for the Sensitization of Chemoresistant Ovarian Cancer Cells.
Harper AK; Fletcher NM; Fan R; Morris RT; Saed GM
Reprod Sci; 2020 Apr; 27(4):1030-1036. PubMed ID: 32124395
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum to "Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest" (Exp. Mol. Pathol. 2016 100(3) 506-13).
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Aug; 101(1):163. PubMed ID: 27392408
[No Abstract] [Full Text] [Related]
9. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.
Kim SW; Kim JW; Kim YT; Kim JH; Kim S; Yoon BS; Nam EJ; Kim HY
Genes Chromosomes Cancer; 2007 Jan; 46(1):1-9. PubMed ID: 17044060
[TBL] [Abstract][Full Text] [Related]
10. Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy.
Deng J; Wang L; Ni J; Beretov J; Wasinger V; Wu D; Duan W; Graham P; Li Y
Expert Rev Proteomics; 2016 Oct; 13(10):905-915. PubMed ID: 27598304
[TBL] [Abstract][Full Text] [Related]
11. Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer.
Emmings E; Mullany S; Chang Z; Landen CN; Linder S; Bazzaro M
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626133
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.
Kobayashi N; Abedini M; Sakuragi N; Tsang BK
J Ovarian Res; 2013; 6():7. PubMed ID: 23351152
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Fauci JM; Sabbatino F; Wang Y; Londoño-Joshi AI; Straughn JM; Landen CN; Ferrone S; Buchsbaum DJ
Gynecol Oncol; 2014 Jan; 132(1):203-10. PubMed ID: 24216048
[TBL] [Abstract][Full Text] [Related]
15. Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy.
Lam T; Aguirre-Ghiso JA; Geller MA; Aksan A; Azarin SM
Biotechnol Bioeng; 2020 Oct; 117(10):3066-3080. PubMed ID: 32589792
[TBL] [Abstract][Full Text] [Related]
16. 4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer.
Lokman NA; Price ZK; Hawkins EK; Macpherson AM; Oehler MK; Ricciardelli C
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31443261
[TBL] [Abstract][Full Text] [Related]
17. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
Cornelison R; Dobbin ZC; Katre AA; Jeong DH; Zhang Y; Chen D; Petrova Y; Llaneza DC; Steg AD; Parsons L; Schneider DA; Landen CN
Clin Cancer Res; 2017 Nov; 23(21):6529-6540. PubMed ID: 28778862
[No Abstract] [Full Text] [Related]
18. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells.
Cacan E
J Chemother; 2017 Jun; 29(3):173-178. PubMed ID: 28102109
[TBL] [Abstract][Full Text] [Related]
19. IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Deo AN; Thorat R; Dhadve AC; De A; Rekhi B; Ray P
Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166282. PubMed ID: 34600083
[TBL] [Abstract][Full Text] [Related]
20. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
